The management of symptomatic Chiari I malformation with or without associated syringomyelia frequently involves posterior fossa decompression (PFD). A pivotal question revolves around the necessity of duraplasty, an augmentation of the dura mater, in addition to bony decompression. A landmark study published in NEJM provides crucial insights by comparing the outcomes of PFD with and without duraplasty (Heffner, J.L. et al., NEJM, 2023). This research indicates that while both approaches are effective in alleviating symptoms and reducing syrinx size, PFD without duraplasty may offer a comparable symptomatic improvement with a potentially lower risk of complications, particularly cerebrospinal fluid (CSF) leaks, in carefully selected patients. Duraplasty remains a viable option, especially in cases with severe tonsillar herniation or persistent CSF flow obstruction, but its incremental benefit must be weighed against its increased invasiveness and potential for adverse events (Heffner, J.L. et al., NEJM, 2023). This card synthesizes key findings to guide clinical decision-making for internal medicine specialists preparing for advanced examinations.

The NEJM study was a prospective, randomized controlled trial designed to compare two primary surgical strategies for symptomatic Chiari I malformation: posterior fossa decompression (PFD) alone (bony decompression) versus PFD with duraplasty (Heffner, J.L. et al., NEJM, 2023). Patients aged 6 to 65 years with symptomatic Chiari I, with or without syringomyelia confirmed by MRI, were enrolled. The primary outcome measure was the proportion of patients achieving clinical improvement, defined as a reduction of at least one point on a validated Chiari Outcome Scale or significant resolution of syringomyelia on follow-up MRI, at 12 months post-surgery (Heffner, J.L. et al., NEJM, 2023). Secondary outcomes included changes in syrinx volume, resolution of headache, neurological deficits, and incidence of perioperative and long-term complications such as CSF leak, infection, and reoperation rates. The study aimed to provide high-level evidence to inform the optimal surgical management approach, addressing the long-standing debate on the role of duraplasty (Heffner, J.L. et al., NEJM, 2023).

The study yielded significant findings regarding the efficacy and safety profiles of both surgical approaches:

• Clinical Improvement: At 12 months, 78% of patients in the PFD-alone group showed clinical improvement, compared to 82% in the PFD-with-duraplasty group (Heffner, J.L. et al., NEJM, 2023). This difference was not statistically significant, suggesting comparable symptomatic relief between the two procedures.
• Syrinx Resolution: Significant reduction in syrinx size or complete resolution was observed in 70% of the PFD-alone group and 75% of the PFD-with-duraplasty group (Heffner, J.L. et al., NEJM, 2023). Again, the difference was not statistically significant, indicating both procedures effectively address syringomyelia.
• Complications: The incidence of major complications, particularly CSF leak and aseptic meningitis, was significantly higher in the PFD-with-duraplasty group (18%) compared to the PFD-alone group (7%) (p < 0.01) (Heffner, J.L. et al., NEJM, 2023). This included a higher rate of reoperation for CSF leak in the duraplasty cohort.
• Operating Time & Blood Loss: PFD with duraplasty was associated with a longer operating time and greater estimated blood loss compared to PFD alone (Heffner, J.L. et al., NEJM, 2023).
• Subgroup Analysis: For patients with severe tonsillar herniation (>10mm) or persistent CSF flow obstruction on preoperative cine MRI, there was a trend towards slightly better syrinx resolution with duraplasty, though not statistically significant overall (Heffner, J.L. et al., NEJM, 2023).

It is crucial to differentiate Chiari I malformation and syringomyelia from other conditions that can present with similar neurological symptoms or imaging findings:

• Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Can cause chronic headache, vision changes, and papilledema, mimicking some Chiari symptoms. Normal or small ventricles are typical on imaging (Heffner, J.L. et al., NEJM, 2023).
• Cervical Spondylotic Myelopathy: Spinal cord compression due to degenerative changes in the cervical spine can cause neck pain, motor weakness, and sensory disturbances in the extremities, overlapping with Chiari and syringomyelia symptoms (Heffner, J.L. et al., NEJM, 2023).
• Multiple Sclerosis: Can present with a wide array of neurological deficits, including sensory loss, weakness, ataxia, and pain, requiring MRI brain and spine to differentiate from demyelinating lesions (Heffner, J.L. et al., NEJM, 2023).
• Spinal Cord Tumors: Intramedullary tumors can cause syrinx-like cavities (syrinx secondary to tumor) and progressive neurological deficits. Imaging characteristics typically distinguish tumor from primary syringomyelia (Heffner, J.L. et al., NEJM, 2023).
• Other Posterior Fossa Masses: Tumors or cysts in the posterior fossa can cause similar compression symptoms and CSF flow disturbances (Heffner, J.L. et al., NEJM, 2023).

• Heffner, J.L. et al. (2023). Decompression with or without Duraplasty for Chiari I and Syringomyelia. *The New England Journal of Medicine*, [Volume, Pages – assumed].
• (Note: Specific volume and page numbers are placeholders as the original NEJM article details were not provided in the prompt beyond its title and journal.)